LOXO-195 is a selective TRK inhibitor that is being investigated to address potential mechanisms of acquired resistance that may emerge in patients receiving VITRAKVI® (larotrectinib) or other multikinase inhibitors with anti-TRK activity.
Acquired resistance to targeted therapies has proven to be an important component of long-term cancer care and targeted therapy drug development. LOXO-195 was developed in anticipation of potential resistance to VITRAKVI® (larotrectinib), and in light of recent published literature regarding emerging mechanisms of resistance to TRK inhibition. With the LOXO-195 program, Loxo Oncology seeks to potentially extend the duration of disease control for patients with TRK fusion cancers.
LOXO-195 is currently being evaluated in a Phase 1/2 trial. For more information about the LOXO-195 clinical trial, please refer to clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology TRK Physician and Patient Clinical Trial Hotline for more information about the LOXO-195 clinical trial at 1-855-NTRK-123 or email email@example.com.
In July 2017, we initiated a multi-center, open-label Phase 1/2 trial in patients with TRK fusion cancers who have progressed while receiving another TRK inhibitor or are intolerant to another TRK inhibitor.
For additional information about the LOXO-195 clinical trial, please refer to www.clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123.
Policy for Access to Investigational Agents
Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology’s Policy for Access to Investigational Agents describes the principles that the company will follow when considering a request, view here.
Data presented at the 2016 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics illustrated the potency, specificity, and favorable in vivo properties in animals of LOXO-195, our clinical candidate.
A research brief published in Cancer Discovery in June 2017 outlines the preclinical rationale for LOXO-195 and clinical proof-of-concept data from the first two patients treated. Read the publication here.